» Articles » PMID: 39200999

Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD)

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Aug 29
PMID 39200999
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) is likely to be approaching 38% of the world's population. It is predicted to become worse and is the main cause of morbidity and mortality due to hepatic pathologies. It is particularly worrying that NAFLD is increasingly diagnosed in children and is closely related, among other conditions, to insulin resistance and metabolic syndrome. Against this background is the concern that the awareness of patients with NAFLD is low; in one study, almost 96% of adult patients with NAFLD in the USA were not aware of their disease. Thus, studies on the therapeutic tools used to treat NAFLD are extremely important. One promising treatment is a well-formulated ketogenic diet (KD). The aim of this paper is to present a review of the available publications and the current state of knowledge of the effect of the KD on NAFLD. This paper includes characteristics of the key factors (from the point of view of NAFLD regression), on which ketogenic diet exerts its effects, i.e., reduction in insulin resistance and body weight, elimination of fructose and monosaccharides, limitation of the total carbohydrate intake, anti-inflammatory ketosis state, or modulation of gut microbiome and metabolome. In the context of the evidence for the effectiveness of the KD in the regression of NAFLD, this paper also suggests the important role of taking responsibility for one's own health through increasing self-monitoring and self-education.

Citing Articles

A Ketogenic Diet Followed by Gradual Carbohydrate Reintroduction Restores Menstrual Cycles in Women with Polycystic Ovary Syndrome with Oligomenorrhea Independent of Body Weight Loss: Results from a Single-Center, One-Arm, Pilot Study.

Rossetti R, Strinati V, Caputi A, Risi R, Spizzichini M, Mondo A Metabolites. 2024; 14(12).

PMID: 39728472 PMC: 11678147. DOI: 10.3390/metabo14120691.


The Impact of a Ketogenic Diet on Late-Stage Pancreatic Carcinogenesis in Mice: Efficacy and Safety Studies.

Cortez N, Bacha T, Ead A, Rodriguez Lanzi C, Lacroix C, Franceschetti A Nutrients. 2024; 16(22).

PMID: 39599705 PMC: 11597385. DOI: 10.3390/nu16223919.


Bilirubin, a hepatoprotective agent that activates SIRT1, PGC-1α, and PPAR-α, while inhibiting NF-κB in rats with metabolic-associated fatty liver disease.

Taghizadeh M, Maleki M, Vakili O, Tavakoli R, Zarei P, Dehghanian A Sci Rep. 2024; 14(1):29244.

PMID: 39587213 PMC: 11589846. DOI: 10.1038/s41598-024-80119-5.

References
1.
Pinto A, Bonucci A, Maggi E, Corsi M, Businaro R . Anti-Oxidant and Anti-Inflammatory Activity of Ketogenic Diet: New Perspectives for Neuroprotection in Alzheimer's Disease. Antioxidants (Basel). 2018; 7(5). PMC: 5981249. DOI: 10.3390/antiox7050063. View

2.
Sharpton S, Ajmera V, Loomba R . Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol. 2018; 17(2):296-306. PMC: 6314895. DOI: 10.1016/j.cgh.2018.08.065. View

3.
Tsai E, Lee T . Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2017; 22(1):73-92. DOI: 10.1016/j.cld.2017.08.004. View

4.
Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

5.
Tincopa M, Lyden A, Wong J, Jackson E, Richardson C, Lok A . Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2021; 67(2):481-491. PMC: 8090923. DOI: 10.1007/s10620-021-06922-6. View